CBR1 and metabolic dysfunction-associated steatohepatitis: The first biologic drug targeting the ECS, namacizumab, a negative allosteric modulating antibody (NAMA) that stabilizes CBR1 in an inactive conformation, was approved to initiate a phase 1 of the clinical trial in the treatment of non‐alcoholic steatohepatitis (NASH) and diabetic nephropathy.74